Quantcast

Latest glioblastoma multiforme Stories

2014-07-02 16:24:28

In this phase two study, 50 percent of glioblastoma patients lived for two years, an encouraging result for one of the most deadly cancers that often kills patients within one year of diagnosis CHICAGO, July 2, 2014 /PRNewswire-USNewswire/ -- Patients newly diagnosed with glioblastoma multiforme (GBM) and treated with an experimental cancer vaccine made from the patient's own tumor in addition to standard of care lived longer compared to those who received standard of care alone,...

2014-06-30 08:30:17

SAN ANTONIO, June 30, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, releases the 2014 BIO International presentation by Chairman and CEO, Craig Dionne, PhD from the 2014 BIO International Convention held June 24th in San Diego, California. Dr. Dionne presented interim results from the Phase Ib and ongoing Phase II study for lead drug candidate, G-202. Summary: -- G-202 Data in Hepatocellular (HCC) Patients...

2014-06-27 14:56:01

German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) A clinical phase I trial to examine the safety of the vaccine against gliomas based on mutant IDH1 in human patients is planned Astrocytomas and oligodendrogliomas are subtypes of a brain cancer called 'glioma'. These incurable brain tumors arise from glial cells, a type of support cell found in the central nervous system. "Low-grade gliomas", which grow comparatively slowly, spread in a diffuse manner across the...

2014-06-27 12:26:56

HOUSTON, June 27, 2014 /PRNewswire/ -- The Burzynski Research Institute, Inc. (BRI) announced today that it will present data on two of the Company's clinical-stage product candidates, Antineoplaston A10 injections (Atengenal(®)) and Antineoplaston AS2-1 injections (Astugenal(®)), at the 16(th) International Symposium on Pediatric Neuro-Oncology held in Singapore from June 28, 2014 to July 2, 2014. Abstracts and presentations are now available to the public in an online supplement...

2014-06-24 16:24:29

G-202 Data in HCC Patients (Phase I and Phase II) Highly Suggestive of Positive Clinical Activity SAN ANTONIO, June 24, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, releases the 2014 BIO International corporate presentation. Chairman and CEO, Craig Dionne, PhD, presented the company overview and clinical trial updates for G-202 at the 2014 BIO International Convention, today, Tuesday, June 24th, at...

2014-06-24 08:31:08

U.S. Phase 2a Clinical Trial in Recurrent Glioblastoma to Initiate in Early 2015 SYDNEY, June 24, 2014 /PRNewswire/ -- EnGeneIC, Ltd., an emerging biopharmaceutical company focused on revolutionizing the treatment of cancer through the targeted delivery of therapeutic agents directly to cancer cells, today announced plans to move forward with a Phase 2a clinical trial in the U.S. using its formulation of EGFR-targeted, EDV(TM) nanocells packaged with doxorubicin for the treatment...

2014-06-23 08:28:38

SAN ANTONIO, June 23, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, releases the updated corporate video explaining its lead drug candidate, G-202. The video explains, "The thapsigargin plant, a weed that grows abundantly in the Mediterranean, kills by disruption of the calcium balance in cells, all cells. Now, Genspera has targeted its active ingredient thapsigargin, to kill only the cells we select:...

2014-06-20 08:23:49

Company Refutes Latest Feuerstein False Headline and Attacks BETHESDA, Md., June 20, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today refuted Adam Feuerstein's latest false headline and attack on the Company, and reaffirmed the Company's recent interim data announcements from its Phase I/II clinical trial of DCVax-Direct for all inoperable solid tumors....

2014-06-19 08:28:56

SAN ANTONIO, June 19, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCQB:GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces that Chairman and CEO, Craig Dionne, PhD, will deliver a company overview at the 2014 BIO International Convention, on Tuesday, June 24(th), at 11:15 PDT, in San Diego, CA (http://mybio.org/search/all?terms=GenSpera). Dr. Dionne will give an update of the ongoing G-202 Phase II trials in both hepatocellular carcinoma and...

2014-06-18 23:02:56

New research report “Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2019 - Growth to Hinge on the Success of Personalized Vaccine Following Early Approval in Germany” elaborated by GBI Research is now available at MarketPublishers.com. According to the study, in 2019, the world GBM market value is anticipated to amount to USD 583 million. London, UK (PRWEB) June 18, 2014 Owing to the poor prognosis under presently available treatment options, therapies with high...


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related